Abstract:
This disclosure generally relates to methods of making ibuprofen, naproxen, and derivatives thereof. This disclosure also generally relates to compounds made by the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Abstract:
A system comprising a) Ni(0) b) from 4 to 10 mol per mol of Ni(0) in a) of a compound (I) of the formula P(X1R1)(X2R2)(X3R3) (I) where X1, X2, X3 are each, independently of one another, oxygen or a single bond, R1, R2, R3 are, independently of one another, identical or different organic radicals and c) from 1 to 4 mol per mol of Ni(0) in a) of a compound (II) of the formula where X11, X12, X13 X21, X22, X23 are each, independently of one another, oxygen or a single bond, R11, R12 are identical or different, individual or bridged organic radicals, R21, R22 are identical or different, individual or bridged organic radicals and Y is a bridging group is suitable as catalyst for preparing mixtures of monoolefinic C5 mononitriles having nonconjugated C═C and C═N bonds by hydrocyanation of a 1,3-butadiene-containing hydrocarbon mixture and for preparing a dinitrile by hydrocyanation of a mixture of monoolefinic C5 mononitriles having nonconjugated C═C and C═N bonds.
Abstract:
The present invention relates to an efficient process for preparing an arylcyclopropanecarbonitrile, which involves the use of sulfolane as a solvent.
Abstract:
A process is described for preparing 3-pentenenitrile by hydrocyanating 1,3-butadiene in the presence of at least one catalyst, wherein the reaction is carried out in a loop reactor having external pumped circulation and jet nozzle for driving the internal circulation.
Abstract:
Compounds of formula (I): ##STR1## wherein: R.sup.1 is alkyl; R.sup.2a, R.sup.2b, R.sup.2c and R.sup.2d are the same or different and each is hydrogen, optionally substituted alkyl, --(C.dbd.O)--B.sup.1 (wherein B.sup.1 is hydrogen or alkyl), nitro, --NR.sup.c R.sup.d (wherein R.sup.c is hydrogen or alkyl and Rd is alkyl), hydroxy, protected hydroxy group, alkoxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl or halogen;R.sup.3 is alkyl; R.sup.4 is a group of the formula (II) ##STR2## wherein A.sup.1 is a single bond, alkylene or alkenylene; R.sup.5a and R.sup.5b are the same or different and each is hydrogen, alkyl or --A.sup.4 R.sup.5.sub.c wherein A is a single bond, alkylene or alkenylene and R.sup.5.sub.c is alkoxy; and n is 0, and pharmaceutically acceptable salts thereof. Such compounds have valuable inhibitory activity against acyl-CoA (cholesterol acyl transferase).
Abstract:
The present invention relates to compounds of the formula (I) or a tautomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, tautomer or prodrug, wherein: R1, R2, R3, R4 and R5 are each independently selected from H, halo, CN, CF3 and CONH2; compositions containing such compounds and the uses of such compounds as antiparasitic agents.
Abstract:
The present invention provides a holographic recording composition comprising a compound denoted by general formula (I) and a holographic recording medium comprising a recording layer, wherein the recording layer comprises a compound denoted by general formula (I). In general formula (I), R1 denotes a hydrogen atom or a substituent having a Hammett value, σp, of equal to or greater than −0.30, each of R2, R3, R4, R5, and R6 independently denotes a hydrogen atom or a substituent, each of A and B independently denotes a substituent and a combination of A and B is (cyano group, cyano group), (oxycarbonyl group, oxycarbonyl group), (acyl group, acyl group), (sulfonyl group, sulfonyl group), (cyano group, acyl group), (cyano group, sulfonyl group), (oxycarbonyl group, acyl group), (oxycarbonyl group, sulfonyl group), or (sulfonyl group, acyl group), and at least one of R1, R2, R3, R4, R5, R6, A, and B comprises a polymerizable group.
Abstract:
Hexamethylenediamine and aminocapronitrile are simultaneoussly produced by hemihydrogenation of adiponitrile, which includes a stage of separation of the hexamethylenediamine from the hydrogenate by distillation of the hexamethylenediamine, the distillation of the hexamethylenediamine being carried out from the hydrogenate containing a free acid and/or an alkali metal or ammonium acid salt, whereby a top fraction A recovered at the column top of the stage of distillation of the hexamethylenediamine is essentially crude hexamethylenediamine and a small amount of THA; the amount of THA (tetrahydroazepine) present in the crude hexamethylenediamine constitutes a small proportion of the THA present in the hydrogenate.